MADHAVBAUG Vaidya Sane Ayurved Laboratories Q2 FY26 results (Jul–Sep 2025) and concall
Madhavbaug reported strong financial performance in H1 FY26, with significant revenue and profit growth driven by higher patient engagement and improved operational efficiency. The company is actively expanding its hospital bed capacity, adding new clinics, and has initiated its first international venture in Malaysia. Strategic initiatives include a focus on disease reversal programs, deepening insurance partnerships, and in-house manufacturing for better margins, while awaiting NSE approval for warrant funds.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 2.0%, net profit up 400.0% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 46 | 54 | 51 | 48 | 42 −9% | 48 −11% | 50 −2% |
| EBITDA | 4 | 4 | 3 | 2 | 6 +50% | 9 +125% | 9 +200% |
| Net profit | 3 | 2 | 1 | 1 | 4 +33% | 3 +50% | 5 +400% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
